



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH





European Network of Centres for
Pharmacoepidemiology and
Pharmacovigilance

Declaration on compliance with the ENCePP Code of Conduct for ENCePP Studies¹

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare for the purpose of conducting the study International Active Surveillance Study of Women Taking Dienogest for Endometriosis: Visanne Post-approval Observational Study (VIPOS):
Registration No:

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the ENCePP Code of Conduct adopted on 21 / 10 / 2010;
- to inform the ENCePP Secretariat, without delay, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator: Juergen Dinger Date: 21 / 10 / 2010 (xx/yy/yyyy) Stamp (if applicable) and signature: 	ZEG Zentrum für Epidemiologie und Gesundheitsforschung Berlin GmbH Invalidenstraße 115 10115 Berlin
Name of the coordinating study entity: ZEG Berlin Address: Invalidenstrasse, 115 10115 Berlin	
Name of person authorised to sign on behalf of the coordinating study entity [if different from (primary) lead investigator]: Clare Barnett Date: 21 / 10 / 2010 (xx/yy/yyyy) Stamp (if applicable) and signature: 	

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct for ENCePP Studies.

¹ Complete the declaration on screen, then print, stamp (if applicable) and sign.